Published in final edited form as:

Antiviral Res. 2013 September ; 99(3): 405–408. doi:10.1016/j.antiviral.2013.06.019.

Safety of coitally administered tenofovir 1% gel, a vaginal microbicide, in chronic hepatitis B virus carriers: Results from the CAPRISA 004 trial

Cheryl BAXTER^{a,*}, Nonhlanhla YENDE-ZUMA^a, Phindile TSHABALALA^a, Quarraisha ABDOOL KARIM^{a,b}, and Salim S ABDOOL KARIM^{a,b}

Cheryl BAXTER: baxterc1@ukzn.ac.za; Nonhlanhla YENDE-ZUMA: yende@ukzn.ac.za; Phindile TSHABALALA: tshabalala@ukzn.ac.za; Quarraisha ABDOOL KARIM: abdoolq2@ukzn.ac.za; Salim S ABDOOL KARIM: karims1@ukzn.ac.za

^aCentre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa

^bDepartment of Epidemiology, Mailman School of Public Health, Columbia University, New York, USA

Abstract

Tenofovir disoproxil fumarate, a licensed oral treatment for both HIV and Hepatitis B virus (HBV) infections, has been associated with severe rebound hepatic flares when treatment is interrupted. A gel formulation of tenofovir is currently being assessed as a microbicide against HIV. If licensed, it is possible that tenofovir gel could be used either intentionally or unintentionally by HBV carriers. The purpose of this study was to establish the safety of tenofovir gel use in this patient group participating in the CAPRISA 004 tenofovir gel trial. HBV infection status was assessed at enrolment and study exit. Liver function testing was performed at enrolment, study months 3, 12, 24, study exit, and two months after exiting the study. At enrolment, 34 women were identified as being HBV carriers and 22 women acquired HBV infections during follow-up; 14 and 8 in the tenofovir and placebo gel arms respectively ($p=0.21$). Intermittent tenofovir gel use did not cause an increase in hepatic flares or impact on viral load suppression in women with HBV infection. There were 2 hepatic flares in each gel arm during follow-up and none two months after cessation of gel at study exit. The mean HBV DNA levels were similar at enrolment and exit in both study arms. Tenofovir gel, when used intermittently, was safe to use in women with HBV infection.

© 2013 Elsevier B.V. All rights reserved.

Address for correspondence: Mrs Cheryl Baxter, CAPRISA, 2nd K-RITH Tower Building, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Private Bag X7, Congella, 4013. baxterc1@ukzn.ac.za, Telephone: +2731 260 4559, Fax: +27 31 260 4549.

Conflict of interest:

Quarraisha Abdool Karim was the Co-Principal investigator of the HPTN Prevention Leadership Group (NIH/NIAID U01 AI068619). Salim S Abdool Karim was the Protocol Chair of the HPTN 035 trial which was supported by the National Institutes of Health (grant # U01AI46749 and U01AI068633). Salim Abdool Karim and Quarraisha Abdool Karim are co-inventors of two pending patents (61/354,050 and 61/357,892) of tenofovir gel against HSV-1 and HSV-2 with scientists from Gilead Sciences. Gilead Sciences did not have any role in the experiments or analyses presented here. The other authors have no financial conflicts of interest.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Keywords

microbicides; Hepatitis B virus; tenofovir gel; HIV prevention; hepatic flares

Tenofovir 1% gel, a vaginal microbicide, has been shown to reduce HIV acquisition by 39% when used intermittently before and after sex (Abdool Karim et al., 2010). Research is underway to obtain the additional data for licensure as tenofovir 1% gel has the potential to alter the HIV epidemic trajectory, particularly in sub-Saharan Africa (Williams et al., 2011).

Tenofovir disoproxil fumarate (the oral formulation of tenofovir), is already licensed for the treatment of both HIV and HBV. However, one of the potential side effects of using tenofovir in individuals with HBV infection is a relapse of hepatitis symptoms (“flares”) when the drug is withdrawn (Lim et al., 2002; Nuesch et al., 2008; Puoti et al., 2006). Even though it is not known whether the hepatic flares associated with the use of oral tenofovir also apply to the gel formulation, HBV carriers are often excluded from antiretroviral-based microbicide trials.

In order for tenofovir 1% gel to have an appreciable impact on HBV viremia, it would need to be absorbed systemically. Pharmacokinetic studies have shown that intravaginally administered tenofovir 1% gel is systemically absorbed. However, topical application leads to substantially lower drug concentrations in plasma than that achieved following oral administration of tenofovir (Hendrix et al., 2013; Kashuba, 2008; Schwartz et al., 2011) and may therefore have limited impact on HBV viremia.

However, given that tenofovir 1% gel could be used either intentionally or inadvertently by chronic hepatitis B infected individuals at risk of acquiring HIV infection, it is important to establish whether it was safe to use the gel formulation of tenofovir in women who are infected with HBV, which has not been established in any clinical.

The potential risks of intermittent use of tenofovir 1% gel were assessed in a subgroup of women who were already infected with hepatitis B or acquired infection during the CAPRISA 004 trial. Details of the CAPRISA 004 tenofovir gel trial procedures have been described in detail previously (Abdool Karim et al., 2010). In brief, enrolled women were randomly assigned in equal proportions to receive one of two identically looking study gels: tenofovir 1% gel or placebo gel. Women were requested use the gel in relation to coitus; to insert one dose of gel within 12 hours before sex and a second dose of gel as soon as possible within 12 hours after sex and no more than two doses of gel in a 24-hour period. Gel adherence was assessed each month by counts of returned empty applicators. Participants had a rapid HIV test each month.

Hepatitis B status was established using routine Hepatitis B virus serology (Abbott Architect C8200, Abbott Laboratories, Detroit, MI) testing conducted at the enrolment and exit visits and included Hepatitis B surface antigen (HBsAg), antibodies to HBsAg (anti-HBs), antibodies to HBcAg (anti-HBc), IgM anti-HBc, and “e” antigen (HBeAg). HBV DNA levels (COBAS TaqMan HBV test, Roche, Branchburg, NJ) were established retrospectively on stored samples. Hepatic flares, defined as alanine transaminase (ALT) 5 x the upper limit of normal (ULN), were assessed by liver function tests performed at enrolment, during the trial when clinically indicated, and at study months 3, 12 and 24, and at study exit.

The statistical analysis included the Fisher’s exact test, Wilcoxon two- sample test and Wilcoxon signed rank test for paired samples. The log rank test was used to compare the incidence of HBV between the two treatment arms.

This sub-study was approved by the University of KwaZulu-Natal's Biomedical Research Ethics Committee (BE025/010).

Of the 889 eligible women enrolled in the CAPRISA 004 trial (Figure 1), HBsAg was detected at enrolment in 34 (3.8%) women (chronic HBV carriers), combined anti-HBc and anti-HBs, indicating established immunity from prior infection, in 230 (25.9%), anti-HBc only in 17 (1.9%), and anti-HBs only, indicating established immunity from vaccination, in 16 (1.8%). HBeAg, a marker of active viral replication, was detected in only 9% (3/34) of all HBsAg positive women. The remaining 592 (66.6%) women had no markers of HBV exposure (Figure 1).

By comparing HBV status at study exit with that at study entry, it was retrospectively established that 22 women acquired HBV infection during the 878.7 women-years (mean=18 months) of follow-up: 14 and 8 in the tenofovir and placebo gel arms respectively. The HBV incidence rate in the tenofovir 1% gel arm was 3.2 per 100 women-years (wy) (95% CI:1.7, 5.3) compared to 1.8 per 100 wy (95% CI:0.8, 3.6) in the placebo gel arm (IRR=1.8; 95% CI:0.7, 4.8; $p=0.21$). By study exit, 19 of these 22 women (86.4%) with newly acquired HBV infection during trial follow-up had developed antibodies and 13.6% (3/22) were still chronic HBV carriers (Figure 1). Therefore, a total of 37 women were identified as being persistently HBsAg positive during the trial; 34 at enrolment and a further 3 by study exit.

Gel was used on average 5.9 (median: 5.7) and 5.9 (median:5.2) times per month in women in the tenofovir 1% and placebo gel groups respectively. In the 37 chronic HBV carriers, tenofovir 1% gel was used on average 5.5 (median:4.3) times per month.

Overall, the number of liver-related adverse events in women in the tenofovir 1% gel and the placebo gel groups was similar, regardless of HBV status (Table 1). In women with chronic HBV infection, there were two cases of hepatic flares in each study arm and none of the chronic HBV carriers were temporarily discontinued from using product for liver-related adverse events. Among women who remained HBV uninfected throughout the study ($n=551$), there were three hepatic flares in each study arm ($p=0.51$). Tenofovir gel did not impact on HBV DNA in chronic HBV carriers (see supplementary appendix).

There was no increase in the number of HBV-associated hepatic flares in women using tenofovir 1% gel. These results extend the current safety profile of tenofovir 1% gel. Previous data from the CAPRISA 004 trial showed that intermittent tenofovir 1% gel caused no significant renal, hematological, genital or bone effects (Sokal et al., 2012). As future policy and programs are being developed (WHO/UNAIDS, 2010), this reassuring result indicates that women who have chronic HBV infection need not be excluded from roll-out programs. The low level of liver-related adverse events and hepatic flares observed in this study are most likely explained by the low systemic levels of tenofovir following gel administration. One pharmacokinetic study has shown that tenofovir concentrations in the blood reach 4ng/mL while cervicovaginal concentrations of up to 1.9×10^6 ng/mL are achieved following a single intravaginal dose of tenofovir (Schwartz et al., 2011).

Recent analyses from antiretroviral treatment programs have shown that oral lamivudine- or tenofovir-containing regimens may prevent new HBV infections (Gatanaga et al., 2013; Heuft et al., 2013). A similar prophylactic effect of tenofovir 1% gel on HBV infection was not observed in this study, possibly due to the too low levels of systemic absorption following gel administration. The coitally-linked intermittent dosing regimen would have also contributed to lower levels of systemic absorption compared to daily or more frequent dosing strategies. The extent to which a daily dosing regimen or oral pre-exposure

prophylaxis could have on HBV viremia is not known. More data is needed from larger cohorts that include alternate dosing strategies and formulations.

The moderate sample size limits statistical inference and the generalizability of the results and also our ability to draw any conclusions on the ability of tenofovir gel to prevent HBV. Even with a larger sample size, it is unlikely that the gel formulation will prevent new HBV infections due to the lower levels of systemic absorption achieved. It was also not possible to extrapolate the findings from this study using tenofovir gel to other HIV prevention studies investigating oral tenofovir for HIV prevention. Hepatic flares should continue to be closely monitored in HBV-infected individuals in those studies.

In conclusion, no safety concerns were identified from intermittent use of tenofovir 1% gel by women who were chronic HBV carriers or who developed acute HBV infection while using tenofovir 1% gel as prophylaxis against HIV.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Sources of funding

This study was part of the CAPRISA 004 tenofovir gel trial. The CAPRISA 004 Tenofovir gel trial was supported by the Centre for the AIDS Program of Research in South Africa (CAPRISA), the United States Agency for International Development (USAID), FHI (co operative agreement # GPO-A-00-05-00022-00, contract # 132119), and LIFElab, a biotechnology centre of the South African Department of Science and Technology. Support from CONRAD for the product manufacturing and packaging as well as support from Gilead Sciences for the tenofovir used in the production of gel is gratefully acknowledged. We thank the US National Institutes for Health's (NIH) Comprehensive International Program of Research on AIDS (CIPRA grant # AI51794) and the Columbia University-Southern African Fogarty AIDS International Training and Research Program (AITRP grant # D43TW00231) for the research infrastructure and training that made this trial possible. Cheryl Baxter received support from the NIH-funded University of KwaZulu-Natal's Medical Education Partnership Initiative (MEPI), Enhancing Training, Research and Education (ENTRÉE) programme [grant #: 5R24TW008863]. None of the funders were involved in the design, collection, analysis interpretation of the data, or in the writing of the paper.

This sub-study was conceptualized and designed by SSAK, QAK and CB. The data was gathered, analyzed and interpreted by CB, SSAK, PT, and NY. SSAK, CB, and NY had full access to all of the data in the study and take full responsibility for the integrity of the data and the accuracy of the data analysis. CB took responsibility for writing the paper and all co-authors contributed to critical revisions of the paper.

We thank Dr Paul Feldblum of FHI for his valuable editorial comments on an earlier draft of this manuscript.

We thank the study clinicians, B Mdluli, N Miya, L Mtongana, N Naicker, and Z Omar, who provided clinical care to the participants and the study nurses, DD Chetty, F Dlamini, SD Gumede, Z Gumede, NE Khambule, N Langa, BT Madlala, N Madlala, N Mkhize, ZL Mkhize, M Mlotshwa, C Ndimande, N Ngcobo, C Ntshingila, B Phungula, TE Vumase who were responsible for collecting the biological samples and for clinical care of the participants. We pay tribute to the women who participated in this trial; their dedication and commitment made this study possible. We thank the Health Department of the City of Durban, the traditional leadership of Vulindlela, and members of the Community Advisory Boards at the Vulindlela and eThekweni Research Clinics.

References

- Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany ABM, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D. on behalf of the CAPRISA 004 Trial Group. Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women. *Science*. 2010; 329:1168–1174. [PubMed: 20643915]

- Gatanaga H, Hayashida T, Tanuma J, Oka S. Prophylactic Effect of Antiretroviral Therapy on Hepatitis B Virus Infection. *Clin Infect Dis*. 2013; 56:1812–1819. [PubMed: 23487374]
- Hendrix C, Chen BA, Guddera V, Hoesley C, Justman J, Nakabiito C, Salata R, Soto-Torres L, Patterson K, Minnis AM, Gandham S, Gomez K, Richardson BA, NNB. MTN-001: Randomized Pharmacokinetic Cross-Over Study Comparing Tenofovir Vaginal Gel and Oral Tablets in Vaginal Tissue and Other Compartments. *PLoS One*. 2013; 8:e55013. doi:55010.51371/journal.pone.0055013. [PubMed: 23383037]
- Heuft, M.; van den Berk, G.; Smissaert, T.; Blok, W.; Regez, R.; Dijkman, L.; Brinkman, K. Protective Effect of Hepatitis B Virus-active cART against Primary Hepatitis B Virus Infection [abstract #33]. 20th Conference on Retroviruses and Opportunistic Infections; Atlanta. March 3–6, 2013; 2013.
- Kashuba, A. Genital Compartmentalization of Orally and Topically Administered Antiretrovirals. 15th Conference on Opportunistic Infections and Retroviruses; Boston. 2008.
- Lim SG, Wai CT, Rajnakova A, Kajiji T, Guan R. Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B. *Gut*. 2002; 51:597–599. [PubMed: 12235087]
- Nuesch R, Ananworanich J, Srasuebku P, Chetchotisakd P, Prasithsirikul W, Klinbuayam W, Mahanontharit A, Jupimai T, Ruxrungtham K, Hirschel B. Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection. *AIDS*. 2008; 22:152–154. [PubMed: 18090405]
- Puoti M, Torti C, Bruno R, Filice G, Carosi G. Natural history of chronic hepatitis B in co-infected patients. *J Hepatol*. 2006; 44:S65–70. [PubMed: 16338021]
- Schwartz JL, Rountree W, Kashuba AD, Brache V, Creinin MD, Poindexter A, Kearney BP. A multi-compartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel. *PLoS One*. 2011; 6:e25974. [PubMed: 22039430]
- Sokal DC, Abdool Karim Q, Sibeko S, Yende-Zuma N, Mansoor LE, Baxter C, Grobler A, Frolich J, Kharsany AB, Omar Z, Miya N, Mlisana K, Maarshalk S, Abdool Karim SS. Safety of tenofovir gel, a vaginal microbicide, in South African women: results of the CAPRISA 004 Trial. *Antivir Ther*. 2012;10.3851/IMP2311
- WHO/UNAIDS. Next Steps with 1% Tenofovir Gel - Meeting Report; 25–26 August 2010; Johannesburg, South Africa. 2010.
- Williams BG, Abdool Karim SS, Gouws E, Abdool Karim Q. Epidemiological impact of tenofovir gel on the HIV epidemic in South Africa. *Journal of acquired immune deficiency syndromes*. 2011; 58:207–210. [PubMed: 21654503]

- Tenofovir is associated with hepatic flares in HBV-infected patients who discontinue treatment
- The safety of using a tenofovir-based microbicide was assessed in HBV-infected women
- Tenofovir gel, used intermittently, did not lead to increased hepatic flares in HBV-infected women
- Tenofovir gel had no impact on HBV DNA levels and did not prevent new HBV infections

Figure 1.

Screening, enrolment, randomization and follow-up of the study participants in relation to Hepatitis B infection status in the CAPRISA 004 tenofovir gel trial

*Note: co-enrolments only occurred at the urban site

Table 1
Impact of tenofovir gel on liver-related adverse events (all grades) in women in the CAPRISA 004 tenofovir gel trial

Liver-related adverse events in:	all women		chronic HBV carriers		Incident HBV infected who recovered	
	Tenofovir N=445	Placebo N=444	Tenofovir N=20	Placebo N=17	Tenofovir N=13	Placebo N=6
Elevated liver enzymes^a						
Alanine transaminase (ALT)	10	9	1	3	1	0
Aspartate aminotransferase (AST)	3	5	0	2	0	0
Bilirubin	3	3	0	0	0	0
Gamma-glutamyltransferase (GGT)	5	6	0	1	1	0
Hepatic and hepatobiliary disorders						
Cholestasis	1	2	0	0	0	0
Jaundice	0	1	0	0	0	0

^a Any abnormality, regardless of severity